LTRN Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Lantern Pharma Inc (LTRN) is not a strong buy at this moment for a beginner investor with a long-term strategy. The technical indicators show bearish trends, the options data suggests low trading sentiment, and the financial performance is weak with declining net income and EPS. While the company is advancing its RADR®AI platform, there are no immediate positive catalysts or strong signals to justify a buy recommendation.
The MACD is negative and expanding downward (-0.0225), RSI is neutral at 21.474, and moving averages are bearish (SMA_200 > SMA_20 > SMA_5). The stock is trading near its support level (S1: 2.076), with a pre-market price of 2.08, indicating limited upward momentum.
The company is hosting a webcast to discuss its Q4 and fiscal year 2025 financial results, which may provide insights into its RADR®AI platform and advancements in cancer therapy development.
Weak financial performance in Q3 2025, with net income and EPS declining YoY. No significant insider or hedge fund activity, and no recent congress trading data. Technical indicators are bearish, and the stock has limited short-term growth potential.
In Q3 2025, revenue remained at 0 with no growth YoY. Net income dropped by -7.29% YoY to -$4,177,423, and EPS fell by -7.14% YoY to -$0.39. Gross margin was 0, showing no improvement.
No recent analyst ratings or price target changes available for LTRN.
